Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM. Schouwenburg MG, et al. Among authors: ten tije aj. Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453. Melanoma Res. 2018. PMID: 29750749
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven JJM, Haanen JBAG. van Zeijl MCT, et al. Among authors: ten tije aj. Eur J Cancer. 2021 Feb;144:242-251. doi: 10.1016/j.ejca.2020.11.028. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373869
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ. Jochems A, et al. Among authors: ten tije aj. Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25. Eur J Cancer. 2017. PMID: 28030784
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA. Franken MG, et al. Among authors: ten tije aj. Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628. Anticancer Drugs. 2018. PMID: 29634490
Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM. Jochems A, et al. Among authors: ten tije aj. Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629. Anticancer Drugs. 2018. PMID: 29659371
[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM. van Zeijl MCT, et al. Among authors: ten tije aj. Ned Tijdschr Geneeskd. 2018 Jun 15;162:D2420. Ned Tijdschr Geneeskd. 2018. PMID: 30040270 Dutch.
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT, Ismail RK, de Wreede LC, van den Eertwegh AJM, de Boer A, van Dartel M, Hilarius DL, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Haanen JBAG, Wouters MWJM. van Zeijl MCT, et al. Among authors: ten tije aj. Int J Cancer. 2020 Dec 15;147(12):3461-3470. doi: 10.1002/ijc.33162. Epub 2020 Jul 4. Int J Cancer. 2020. PMID: 32559817 Free PMC article. Clinical Trial.
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study.
van Zeijl MCT, Boer FL, van Poelgeest MIE, van den Eertwegh AJM, Wouters MWJM, de Wreede LC, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Kapiteijn EHW, Haanen JBAG. van Zeijl MCT, et al. Among authors: ten tije aj. Eur J Cancer. 2020 Sep;137:127-135. doi: 10.1016/j.ejca.2020.05.021. Epub 2020 Aug 4. Eur J Cancer. 2020. PMID: 32763783
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT, Haanen JBAG, Wouters MWJM, de Wreede LC, Jochems A, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM, van den Eertwegh AJM. van Zeijl MCT, et al. Among authors: ten tije aj. J Immunother. 2020 Oct;43(8):256-264. doi: 10.1097/CJI.0000000000000334. J Immunother. 2020. PMID: 32804914
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
Verheijden RJ, May AM, Blank CU, van der Veldt AAM, Boers-Sonderen MJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven JJM, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: ten tije aj. ESMO Open. 2020 Nov;5(6):e000945. doi: 10.1136/esmoopen-2020-000945. ESMO Open. 2020. PMID: 33199288 Free PMC article.
96 results